Long
Up..Up..& Away! Priority Review for Cancer Drug
At 8:30 AM NEWS
This morning Myovant Sciences announced priority review for Relugolix for Advanced Prostate Cancer.
The stock should have been up a lot more than what it was on the news but due to the non-circulation of the release, the stock did not move much.
Today at 4:05 PM, after the market closed, the stock started moving higher on more positive news.
At 4:05 PM NEWS
Myovant Sciences to Host Webcast and Conference Call at 8:30 AM EST on June 23, (Tomorrow Morning), to discuss results for Phase 3 SPIRIT 1 Study Evaluating Once-Daily Reglugolix Combination Therapy in Women with Endometriosis.
This company has a lot of positive things moving forward including...
On 6/11/2020, the stock got a boost with a price target of $45.00 a share.
Daily Chart looks good with indicators turning up, Bullish
Weekly Chart also looks Bullish
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
This morning Myovant Sciences announced priority review for Relugolix for Advanced Prostate Cancer.
The stock should have been up a lot more than what it was on the news but due to the non-circulation of the release, the stock did not move much.
Today at 4:05 PM, after the market closed, the stock started moving higher on more positive news.
At 4:05 PM NEWS
Myovant Sciences to Host Webcast and Conference Call at 8:30 AM EST on June 23, (Tomorrow Morning), to discuss results for Phase 3 SPIRIT 1 Study Evaluating Once-Daily Reglugolix Combination Therapy in Women with Endometriosis.
This company has a lot of positive things moving forward including...
On 6/11/2020, the stock got a boost with a price target of $45.00 a share.
Daily Chart looks good with indicators turning up, Bullish
Weekly Chart also looks Bullish
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.